// App-Quantinova.ai

2579 : Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Peter Hillmen

Principal Investigators

  • Jeffrey Szer

  • Ilene C. Weitz

  • Alexander Rth

  • Britta Hoechsmann

  • Jens Panse

  • Kensuke Usuki

  • Morag Griffin

  • Jean-Jacques Kiladjian

  • Carlos M. de Castro

  • Hisakazu Nishimori

  • Lisa Tan

  • Mohamed Hamdani

  • Pascal Deschatelets

  • Cedric Francois

  • Federico Grossi

  • Antonio Risitano

  • Regis Peffault De Latour

Medical Centers

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • Jane Anne Nohl Division of Hematology, Keck School Of Medicine of USC, Los Angeles, CA

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics,German Red Cross Blood Transfusion Service and University Hospital Ulm, Institute of Transfusion Medicine,Ulm,Germany

  • Department of Oncology, Hematology and Stem Cell Transplantation, University Hospital of the RWTH Aachen, Aachen, Germany

  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

  • Centre d'Investigations Cliniques, Hôpital Saint-Louis; Assistance Publique – Hôpitaux de Paris; Université de Paris, Paris, France

  • Duke University College of Medicine, Durham, NC

  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan

  • Lisa Tan Pharma Consulting, Cambridge, United Kingdom

  • AMAG Pharmaceuticals, Inc., Waltham, MA

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

Locations

  • United Kingdom

  • Australia

  • United States

  • Germany

  • Japan

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A


Study Design

  • Randomized

  • Superiority

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A